napabucasin + BBI503

Napabucasin + BBI503 is a combination of two investigational small molecule cancer drugs developed to target cancer stemness and disrupt tumor growth. **Napabucasin** (BBI608) acts as a reactive oxygen species generator and is bioactivated by nicotinamide adenine dinucleotide phosphate quinone oxidoreductase 1 (NQO1), leading to increased oxidative stress in cancer cells and inhibiting pathways such as signal transducer and activator of transcription 3 (STAT3)[1][2]. **BBI503** (amcasertib) is a first-in-class cancer stemness kinase inhibitor targeting cancer stem cell pathways, including STAT3, with activity against both tumor cell proliferation and stemness[5]. Both agents have been evaluated individually and in combination for a range of advanced solid tumors including hepatocellular carcinoma and colorectal cancer[3][4]. This specific drug name refers to the combination of napabucasin and BBI503, although their combination as a clinical product is investigational and may not be widely described outside specific research settings.

Brand names

amcasertib

Other names

cancer stemness inhibitoramcasertib